David Shook - Jul 15, 2024 Form 4 Insider Report for Nkarta, Inc. (NKTX)

Role
Chief Medical Officer, Head of Research & Development
Signature
/s/ Alicia Hager, as Attorney-in-Fact
Stock symbol
NKTX
Transactions as of
Jul 15, 2024
Transactions value $
$0
Form type
4
Date filed
7/31/2024, 04:45 PM
Previous filing
Jun 20, 2024
Next filing
Aug 23, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NKTX Common Stock Award $0 +23.4K +20.1% $0.00 140K Jul 15, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NKTX Stock Option (right to buy) Award $0 +30K $0.00 30K Jul 15, 2024 Common Stock 30K $7.02 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction is inadvertently filed late due to an administrative error.
F2 Represents Restricted Stock Units ("RSUs") which vest in four equal annual installments beginning on August 20, 2025. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.
F3 This option is scheduled to vest and become exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following July 15, 2024.

Remarks:

Chief Medical Officer, Head of Research & Development